Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | CD274 positive |
Therapy | Cisplatin + Paclitaxel + Pembrolizumab |
Indication/Tumor Type | vaginal carcinoma |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
CD274 positive | vaginal carcinoma | sensitive | Cisplatin + Paclitaxel + Pembrolizumab | Guideline | Actionable | Keytruda (pembrolizumab) in combination with Platinol (cisplatin) and Taxol (paclitaxel) is included in guidelines as preferred first-line therapy for patients with recurrent or metastatic vaginal squamous cell carcinoma or adenocarcinoma with CD274 (PD-L1) expression (CPS >/= 1) (NCCN.org). | detail... |
PubMed Id | Reference Title | Details |
---|---|---|
NCCN.org | Full reference... |